Clinically impairing irritability affects 25% to 45% of children with attention-deficit/hyperactivity disorder (ADHD)[@bib1]; yet, the evidence base for treatment selection in the presence of irritability remains thin. This article addresses this knowledge gap by analyzing data from the Multimodal Treatment Study of Children With ADHD (MTA), a large randomized trial comparing various treatment modalities among children with ADHD.[@bib2]

ADHD is among the most common child psychiatric disorders worldwide.[@bib3] It is defined by chronic, pervasive, and impairing symptoms of inattention and hyperactivity/impulsivity.[@bib4] Although irritability, defined by temper outbursts and proneness to anger,[@bib5] is not a diagnostic criterion for ADHD, it is a common presentation in this clinical group[@bib6; @bib7] and is listed under the associated features of ADHD in the *DSM*.[@bib4] In an epidemiological study, 38% of children with ADHD had irritable mood, nearly 10-fold higher over general population rates.[@bib8] This raises the question of how best to treat the subgroup of children with ADHD and irritability.

One approach to this question is to consider irritability as one of the manifestations of behavior problems that are typical of ADHD. Indeed, irritability is characteristic of children with oppositional defiant disorder (ODD), which is highly comorbid with ADHD.[@bib9] Substantial evidence suggests that stimulant treatment also reduces ODD symptoms in those with ADHD[@bib2; @bib10; @bib11] and that parenting interventions may also be useful.[@bib12] However, this is an assumption that needs to be explicitly tested, as mounting evidence indicates that irritable mood is distinct from other, typically headstrong, behaviors characteristic of ODD. This distinction is reflected in the *DSM-5*[@bib4] and is based on research showing that irritability is separable from headstrong behaviors (e.g., argumentativeness, noncompliance, and rule breaking) by virtue of its multivariate structure,[@bib13] longitudinal course,[@bib14; @bib15] external predictions,[@bib16] and genetic associations.[@bib17] In particular, irritability predicts subsequent depression and generalized anxiety, whereas headstrong behaviors predict subsequent delinquent behaviors.[@bib16] If irritability is clinically and etiologically distinct from other behavior problems, irritability in ADHD may also require distinct treatment compared to headstrong behaviors. However, there is little research on the distinctions between these 2 groups of symptoms in children with ADHD[@bib13] or evidence about how best to treat irritable children who have ADHD.

Here we use data from the MTA to address these questions by examining 3 aims. First, we wanted to establish the robustness and clinical relevance of irritability in the MTA. In particular, it is important to know whether irritability in children with ADHD can be distinguished from other typical symptoms of oppositionality, namely, headstrong symptoms. We hypothesized the following: that irritability would be separable from headstrong behaviors in multivariate analyses; that irritability would have different external correlates/consequences (building upon prior investigations,[@bib14] we expected that irritability would significantly differentially predict internalizing symptoms and disorders such as depression and anxiety, whereas the headstrong dimension would differentially predict conduct problems, such as conduct disorder \[CD\]); that irritability would show sufficient longitudinal continuity in children with ADHD such that it could be differentiated from headstrong symptoms; and that irritable and headstrong behaviors each would contribute independently to impairment.

Our second aim was to ascertain how irritability in ADHD responds to treatment with stimulants and/or behavioral therapy. Clinical experience and prior results from randomized controlled treatment studies in children[@bib18; @bib19; @bib20] suggest that stimulant treatment may be useful to treat irritability in ADHD and should be considered as a first-line treatment[@bib1]; however, the evidence is somewhat mixed. Two randomized controlled trials comparing amphetamine and placebo found no beneficial effect of the medication on a broad range of emotional problems, and some studies have found that amphetamine preparations increase irritability and lability.[@bib21] On the other hand, it has recently been shown that children with ADHD and behavior problems that are closely linked to irritability probably respond to behavioral treatment.[@bib22; @bib23] Similarly, a recent meta-analysis of randomized controlled trials[@bib12] has provided evidence from blinded outcomes that behavioral interventions improve parenting and reduce childhood conduct problems in ADHD. To address this matter, we examine 2 competing hypotheses: 1 hypothesis based on the preliminary findings above that suggest stimulant treatment could be helpful; and the other hypothesis, which is that because irritability can be a component of behavior problems such as ODD, it may respond well to behavioral treatment.

The third aim was to establish whether the response to treatment of children with ADHD and irritability differed from that of children without irritability. There is surprisingly little research in this area, although a previous study using MTA data indicated that symptoms of mania do not influence the treatment response to methylphenidate or its side effect profile in children with ADHD.[@bib24] However, this investigation used the 1-month methylphenidate titration trial subset of the MTA and therefore did not include the comparisons with the behavioral interventions nor the treatment outcome after 14 months. A subsequent study by Galanter and colleagues, also using MTA data, showed that children with manic symptoms, as defined using the Child Behavior Checklist (CBCL) dysregulation profile, suffered more morbidity at study onset, yet they also responded to standard ADHD treatment without suffering more side effects compared to children without manic symptoms.[@bib25] This suggests that standard treatment may benefit severely affected children with ADHD; however, the inclusion of anxiety/depression, aggression, and attention in the definition of manic symptoms makes it difficult to estimate the effects of treatment on irritability and on how the presence of irritability may moderate treatment response in children with ADHD. This is particularly important given the separability of irritability from other behavior problems. Hence, in this study, we tested whether the response to MTA treatments, including medication, behavioral treatment, and the combination, varied according to the level of irritability. Our expectation was that while irritable children would show higher levels of ADHD symptoms, they would respond similarly to children low on irritability. In particular, we expect that the previously demonstrated superiority of the medication management over the community comparison and the behavioral treatment arms in the MTA[@bib2] would remain even when accounting for levels of irritability.

Method {#sec1}
======

Participants and Procedure {#sec1.1}
--------------------------

A total of 579 children meeting diagnostic criteria for ADHD Combined Type were recruited from 6 different US sites and randomly assigned to 1 of the following 4 groups: medication management ("MedMgt"; n = 144; 24.9%); behavioral treatment ("Beh"; n = 144; 24.9%); combined treatment ("Comb"; n = 145; 25.0%); or treatment-as-usual community comparison ("CC"; n = 146; 25.2%). The first 3 groups were treated for 14 months in specified protocols. Briefly, MedMgt consisted of a 1-month double-blind titration with methylphenidate for best dose, progressing to an open titration with other drugs, such as d-amphetamine, pemoline, or imipramine if methylphenidate was unsatisfactory. Beh consisted of intense, multi-component individual and group parent training; teacher consultation; a child-directed, 8-week, full-time summer treatment program; and use of a 12-week, half-time classroom behavioral specialist. Comb integrated the MedMgt and Beh strategies, with more extensive assistance from the behavioral therapist to assist in medication adjustment and information from the pharmacotherapist to aid in decision making about escalation of behavioral interventions. The fourth group (CC) was referred for community treatment of the parents\' choosing. The mean age of the children at baseline was 8.5 years (SD = 0.8 years, range = 7--10 years), and 114 children were female (19.7%). Ethnic composition of the sample included 60.8% of white ethnicity, 19.9% African American, and 19.3% Hispanic, racially mixed, or from other ethnic origins. Treatment groups did not differ significantly at baseline on gender, ethnicity, IQ, comorbidity, Conners Parent and Teacher Rating Scales scores, impairment, and medication for ADHD before the study. The only significant difference was age, although all participants were actually in a tight age range (the youngest were in the behavioral treatment group: mean age = 8.3 years; and the oldest were in the medication management group: mean age = 8.6 years). At least 1 parent and all participants in the original MTA study provided written permission and assent for participation before initiation of any study procedures as approved by each site's institutional review board. For the present study, all of the participants from the original study were included. Additional details about the sampling and the procedures in the MTA have been widely described elsewhere.[@bib2; @bib26; @bib27]

Measures {#sec1.2}
--------

The measures relevant to our study are described below. A comprehensive description of the assessment measures used in the MTA has been described elsewhere.[@bib2; @bib28]

ADHD symptom severity was measured by using the mean score of items 1 to 18 of the parent- and the teacher-reported Swanson, Nolan, and Pelham (SNAP) rating scale,[@bib29] which includes the inattention and hyperactivity/impulsivity subscales.

In accordance with previous studies,[@bib14; @bib30] a measure of irritability was generated by adding up the following 3 ODD items on the parent-reported SNAP: "Loses temper"; "Is touchy or easily annoyed by others"; and "Is angry and resentful." The scores ranged from 0 to 9. In addition, a categorical irritability outcome was generated using a median split into high and low irritability and was used for purposes of illustration in several figures. The irritability measure was based on parent-report, given that parents, as compared to teachers, are rated as more useful informants of children's emotional problems.[@bib31; @bib32]

A headstrong dimension was generated by adding up 4 ODD items on the parent-reported SNAP: "Argues with adults," "Actively defies or refuses adult requests or rules," "Does things deliberately that annoy other people," and "Blames others for his or her mistakes or misbehavior." The scores ranged from 0 to 12. The only ODD item not used for either the irritability or the headstrong scales was "Is spiteful or vindictive."

The CBCL was used to assess general psychopathology. The CBCL is a parent-report checklist mapping onto multiple aspects of psychopathology over a 6-month period.[@bib33] Children's global impairment was measured by using the Columbia Impairment Scale--Parent Version (CISP) questionnaire.[@bib34]

Data Analysis {#sec1.3}
-------------

Data analyses for each specific aim were as follows: 1) To establish whether irritability was independent from other ODD symptoms in the MTA sample, we proceeded in 4 ways. First, we explored differences in the multivariate structure using a confirmatory factor analysis (CFA) comparing 2 models (1 versus 2 factors, namely irritability and headstrong behaviors). Second, we explored the longitudinal continuity of each measure (irritability and headstrong behaviors) using path analysis. Third, we explored whether irritability and headstrong behaviors had different correlates in linear regression models in which the 2 variables were introduced as predictors, Finally, we ran a linear regression in which irritability and headstrong behaviors were predictors of impairment to test whether the 2 dimensions contributed independently to it. This is important because impairment can be independent of symptom severity.[@bib35] Significant differences between estimates were judged based on nonoverlapping 95% CI. 2) To test the hypothesis that MedMgt would be superior to Beh in treating irritability, we ran an intent-to-treat (ITT) random-effects regression analysis similar to the original primary analyses but with irritability as the outcome, and time (including baseline, 3-month, 9-month, and 14-month assessments) and treatment group as predictors, as well as the interaction time×treatment group. As in the original MTA study, we also tested for site differences and site-by-treatment effects using the interaction site×treatment group. In statistical terms, our hypothesis was that there would be a significant time-by-treatment group interaction, and that by decomposing this interaction we would find that the MedMgt group (as well as the Comb) would be superior to the Beh group. In addition, we calculated the pre--post effect size of each treatment option by using Cohen's d formula (mean score baseline--mean score at 14 months) / pooled SD. 3) Finally, we tested whether baseline irritability would moderate treatment outcomes, by running an ITT random-effects regression analysis with the severity of the ADHD symptoms as the outcome and, again, time (including baseline, 3-month, 9-month, and 14-month assessments), treatment group, and site as predictors, as well as the interactions irritability×time, irritability×treatment group, time×treatment group, site×treatment group, and irritability×time×treatment group. We also tested whether irritability would differentially affect the response to individual treatments by testing the 3-way interaction of irritability×treatment group×time.

Ethical Approval {#sec1.4}
----------------

The de-identified MTA dataset (MTA96, Version \#1) was provided by the National Institute of Mental Health (NIMH) upon public-access request. The Psychiatry, Nursing, and Midwifery Research Ethics Subcommittee (PNM RESC) at King's College London approved the secondary analysis of these data (reference PNM/13/14-34).

Results {#sec2}
=======

The mean score for the whole sample for the parent-reported irritability subscale derived from the ODD items of the SNAP was 4.30 (SD = 2.48) and the median value was 4. Internal consistency was high (Cronbach's α = .83), and it showed good convergent validity by correlating highly with a scale comprising irritability items from the CBCL (Pearson's correlation r = 0.66, latent correlation r = 0.72). This measure of irritability derived from the CBCL has also been used in previous research.[@bib17] The mean score for the whole sample for the parent-reported headstrong behaviors subscale derived from the ODD items of the SNAP was 6.44 (SD = 3.19), and the median value was 7. This variable also showed high internal consistency (Cronbach's α = 0.83). At baseline, Pearson's correlations of irritability with ADHD symptoms (r = 0.34; *p* \< .001) and with the CISP (r = 0.45; *p* \< .001) were in the medium range.

Aim I: To Establish the Independence of the Irritability Dimension in the MTA Sample {#sec2.1}
------------------------------------------------------------------------------------

The 2-factor model (irritability versus headstrong behaviors) showed a better fit with the data (AIC = 8,640.38; BIC = 8,765.94) compared to the 1-factor model (AIC = 8,751.85; BIC = 8,873.08), as confirmed by difference testing (value = 69.23, df = 1; *p* ≤ .001).

Also, the within-domain stability was significantly stronger than the across-domain stability: irritability at baseline was a better predictor of irritability at 14 months (β = 0.52 \[95% CI = 0.42--0.61\]; *p* ≤ .001) compared to headstrong behaviors at 14 months (β = 0.15 \[95% CI = 0.05--0.25\]; *p* = .004), whereas the headstrong behaviors dimension at baseline was a significantly better predictor of headstrong behaviors at 14 months (β = 0.43 \[95% CI = 0.33−.52\]; *p* ≤ .001) than irritability at 14 months (β = 0.05 \[95% CI = −0.06--0.15\]; *p* = .366). This supports the idea that these constructs are distinct from each other (for more details on the path analytical model, see [Figure S1](#appsec1){ref-type="sec"}, available online).

Irritability was a significantly stronger predictor than headstrong behaviors for the Internalizing Scale at baseline (irritability: β = 0.43 \[95% CI = 0.32--0.54\] versus headstrong behaviors: β = 0.06 \[95% CI = --0.04--0.17\]) as well as at the end of treatment (irritability: β = 0.35 \[95% CI = 0.23--0.47\] versus headstrong behaviors: β = −0.03 \[95% CI = --0.15--0.08\]). Conversely, the headstrong behaviors measure was a significantly stronger predictor of the Externalizing Scale at baseline (irritability: β = 0.29 \[95% CI = 0.21--0.38\] versus headstrong behaviors: β = 0.47 \[95% CI = 0.38--0.55\]) but not at the end of treatment (irritability: β = 0.22 \[95% CI = 0.10--0.33\] versus headstrong behaviors: β = 0.29 \[95% CI = 0.18--0.40\]) (see [Table S1](#appsec1){ref-type="sec"}, available online, for more details).

Finally, irritability and headstrong behaviors each contributed independently to impairment (irritability: β = 0.24, *p* \< .001; headstrong behaviors: β = 0.30, *p* ≤ .001).

Aim II: To Test Whether ADHD Treatments Are Effective at Treating Irritability {#sec2.2}
------------------------------------------------------------------------------

There were no differences in the level of parent-reported irritability at baseline in the 4 treatment groups (F = 0.43, df = 3, *p* = .729). As shown in [Figure 1](#fig1){ref-type="fig"}, overall, irritability scores decreased over the course of the treatment. Means and standard deviations at baseline and at 14 months, as well as pre--post effect sizes for each treatment arm, can be found in [Table 1](#tbl1){ref-type="table"}. The highest effect size corresponded to combined treatment (0.82), followed by medication management (0.63), community comparison (0.48), and behavioral treatment (0.42).

The random-effects regression model included time, treatment group, and site as predictors of change in irritability. Omnibus Wald tests for the effect of site did not reach significance (site: χ^2^ \[5\] = 10.61, *p* = .060; site×treatment: χ^2^ \[15\] = 18.84; *p* = .221); the variable was therefore excluded in a subsequent, more parsimonious model, which included time and treatment group only as predictors of change ([Table 2](#tbl2){ref-type="table"}). Effects of time were significant, indicating that irritability scores decreased significantly over time. Effects of treatment group did not reach significance, indicating that irritability scores in the 4 groups were not significantly different across groups. The interaction time×treatment group was significant, indicating that irritability scores changed differentially according to treatment groups. Decomposition of this interaction ([Table 2](#tbl2){ref-type="table"}) indicated that from the baseline to the end of the treatment (14-month assessment), the MedMgt group were more likely to improve than Beh (coefficient = 0.58; *p* = .021), but not the CC group (coefficient = −0.42; *p* = .095). Those in the Comb group were more likely to improve than those in the Beh (coefficient = −0.87; *p* = .000) and CC (coefficient = −0.71; *p* = .004) groups, but there was no difference between the MedMgt only and Comb (coefficient = −0.29; *p* = .249). It is important to note that the effect sizes of difference between treatments are more modest compared to the effect sizes between pre- and posttreatment for each group. For example, the effect size of the difference between the Comb and CC arms is 0.34, whereas the difference between CC and Beh is −0.05. However, it is worth noting that the magnitude of the difference between ADHD treatments is best accounted for by the random-effects regression model which, unlike the effect sizes, takes into account the heterogeneity across individuals in their responses over time. Effect sizes are displayed in [Table 1](#tbl1){ref-type="table"}.

Aim III: To Test Whether Irritability Moderates Treatment Response of Children With ADHD {#sec2.3}
----------------------------------------------------------------------------------------

Irritability (displayed in [Figure 2](#fig2){ref-type="fig"} as a categorical variable using a median split into high and low irritability for illustration but analyzed dimensionally) did not have a differential effect on the reduction in parent-reported ADHD symptoms across the treatment groups across time. Using the dimensional irritability variable, we formally tested this in a random-effects regression model that included baseline irritability, treatment group, time, and site, with the interactions irritability×time, irritability×treatment, time×treatment, and site×treatment ([Table 3](#tbl3){ref-type="table"}). Omnibus Wald tests for the effect of site did not reach significance (site: χ^2^ \[5\] = 8.29, *p* = .141; site×treatment: χ^2^ \[15\] = 14.15; *p* = .514), for which the variable was excluded in a subsequent, more parsimonious model, which included time, treatment group, and irritability only as predictors of change ([Table 3](#tbl3){ref-type="table"}). In addition, we estimated a 3-way interaction model including time×treatment group×irritability for ADHD symptoms as the outcome. As expected, results of the 3-way interaction were not significant (coefficients ranging from −0.02 to 0.01; *p* values ranging from .481 to .898; full results of this model are presented in [Table S2](#appsec1){ref-type="sec"}, available online). Moreover, the first, more simplified model also presented a better fit compared to the model including the 3-way interaction (AIC = 2924.95 versus 2938.69; BIC = 3064.30 versus 3128.21, respectively).

There was a significant main effect of irritability (reflecting the higher baseline scores of ADHD symptoms in children with high baseline irritability) and a main effect of time (indicating that ADHD scores decreased significantly over time). The effect of site (but not of the interaction site×treatment) was also significant. As shown in [Table 3](#tbl3){ref-type="table"}, the interaction treatment×time reached significance. Decomposition of this interaction showed a better response to treatment for children in the MedMgt and Comb arms compared to those in CC or Beh groups, the same as in the original ITT report.[@bib2]

Additional analyses looked at teacher-rated ADHD as an outcome in the previous model. This was to ensure that the paper\'s main findings held across informant sources, but also because teachers were more likely to be blinded to the treatment condition. As in the case of the parent-rated ADHD, the variable site did not reach significance (site: χ^2^ \[5\] = 5.33, *p* = .377; site×treatment: χ^2^ \[15\] = 12.54; *p* = .638) and therefore was dropped from the model. As can be seen in the lower part of [Table 3](#tbl3){ref-type="table"}, results were very similar to those using the parent-rated ADHD as an outcome, except for the fact that the main effect of irritability did not reach significance in this case. As in the case of the parent-reported ADHD, results of the 3-way interaction time×treatment group×irritability were not significant for the teacher report (see [Table S3](#appsec1){ref-type="sec"}, available online).

Discussion {#sec3}
==========

This study used the MTA data to examine irritability in children with ADHD and its response to different treatments. Our findings were in line with our initial hypothesis that, in children with ADHD, irritability is a separable dimension within the ODD construct. A number of previous studies converge in showing that oppositionality is best thought of as comprising 2 (irritable and headstrong)[@bib17; @bib36] or 3 (irritable, headstrong, and hurtful)[@bib14; @bib15; @bib16; @bib37] dimensions with distinct correlates. We did not have enough items to examine the hurtful dimension in this study, although a previous study suggests that this does exist in children with ADHD.[@bib38] Consistent with previous studies, irritability in this sample contributed to impairment, was more associated with emotional than conduct problems, and showed longitudinal continuity. Thus, irritability in ADHD has the same pattern of multivariate structure and correlates as in children without ADHD. This lends support to the notion that, instead of irritability being an ADHD-specific phenomenon, it is a dimension that cuts across psychopathology in the manner of the Research Domain Criteria (RDoC) conceptualization.[@bib39] However, further studies will be required to determine whether the etiological mechanisms underlying irritability differ between individuals with and without ADHD.

Our second aim was to test the hypothesis that symptoms of irritability would diminish with medication. We found that irritability levels decreased in all treatment arms after 14 months. However, the magnitude of the effect sizes for the irritability response to treatment was approximately half of the magnitude for ADHD symptoms in the original study.[@bib2] In support of our hypothesis, MedMgt was significantly better in reducing irritability than Beh treatment. Surprisingly, MedMgt was not significantly better than CC in reducing irritability (*p* = .095). However, combining MedMgt with Beh treatment was superior to both the Beh treatment alone and the CC intervention, but not compared to MedMgt alone. Beh treatment was not significantly different from the community care intervention. These results show a partial overlap with previous MTA findings regarding other disruptive symptoms. Jensen *et al.*[@bib40] analyzed the response to treatment of oppositional and aggressive behaviors and found that not only the combined treatment, but also MedMgt and Beh treatments alone, were each superior to the CC intervention. Moreover, in that study there were no differences among the 3 active treatments for oppositional/aggressive symptoms except for the fact that the Comb was superior to the Beh intervention.[@bib40] This treatment response difference between irritable and oppositional/aggressive behaviors further suggests that it is important to distinguish between these domains. In light of our findings, it is a possibility that, in the case of irritability, combining medication with behavioral treatment confers advantages given the superiority of the combination, but not MedMgt alone, over the CC, although our results did not actually show superiority of the Comb over MedMgt. Also, our study results indicate that not all irritability remits after standard treatment. Whether adjunct treatments, for example those that have been shown to be effective in treating aggression in ADHD,[@bib41] should be considered for irritability remains to be established.

Finally, we wanted to examine whether high levels of irritability diminished ADHD treatment response. We found that the combined and medication-only treatment arms were superior to the behavioral treatment and the community care interventions at reducing ADHD symptoms, regardless of the level of irritability. This is in keeping with previous reports on the MTA data showing that the comorbidity of ADHD with ODD or CD rarely interacted with treatment response or outcomes.[@bib10; @bib42]

Limitations of this study include the fact that the MTA was not originally designed to examine irritability in children with ADHD, and therefore patient randomization was not stratified by irritability status. Second, the parents in the MTA study were not blinded to treatment group assignments. As such, the extent to which differential outcomes as a function of treatment group were influenced by parental expectations cannot be determined. However, teacher reports of ADHD symptoms were also used as outcomes, and the results were similar to those obtained when using the parent reports. Therefore, considering that teachers were probably blinded (i.e., unlikely to be aware of the treatment allocation),[@bib23] it is unlikely that parental expectations played a relevant role in the teacher-rated results, although it is possible that parental expectations affected the child's behavior in a way that carried over into school. Third, it may well be that we were underpowered to detect a 3-way interaction (irritability×time×treatment group) in our models. However, based on previous simulation results, we have estimated that the sample size required to detect differences among the groups in such a 3-way interaction would be more than 7,000 participants, which is unrealistic for most clinical trials.[@bib43; @bib44] On the other hand, it is reassuring that the graphs shown in [Figure 2](#fig2){ref-type="fig"} did not suggest the presence of this interaction, and if the moderating effect is so small, it is unlikely to be clinically meaningful. Finally, it is worth noting that the community care arm in the MTA study presented with high medication levels (\>70% of children were taking medication for ADHD, albeit with much less consistency/monitoring and lower dosing than the MTA-medicated children) and therefore comparisons against this group should be interpreted with caution.

These results have 2 important clinical implications. First, stimulants---a commonly used and relatively safe class of drugs for ADHD---are also helpful for improving irritability in children with ADHD. Moreover, the combination of stimulants and behavioral treatment could help reduce these symptoms further. Second, irritability symptoms did not have a negative effect on ADHD treatment outcomes. Clinicians can proceed with confidence that ADHD treatments will be effective even in the presence of irritability. These 2 aspects had not been demonstrated in major randomized controlled trials in the field and have long remained an area of clinical uncertainty. Our results may also have etiological implications. Based on the fact that irritability improves with treatments that are effective for ADHD symptoms, it would be tempting to assume that common pathophysiology underlies the overlap between irritability and ADHD. Further research should therefore explore this possibility. Also, future studies should investigate whether ADHD treatment in children with irritable symptoms has a beneficial impact on mood symptoms in the medium-to-long term, given the links between irritability and mood disorders.[@bib45]Clinical Guidance•Irritability is a separable dimension within the ODD construct in children with ADHD.•Standard ADHD treatments are helpful for reducing irritability in children with ADHD.•Irritability symptoms do not seem to influence ADHD treatment outcomes. Clinicians can proceed with confidence that ADHD treatments will be effective even in the presence of irritability.

Supplemental Material {#appsec1}
=====================

Table S1Linear Regressions With the Irritability and Headstrong Dimensions as Predictors and the Child Behavior Checklist (CBCL) Subscales as OutcomesOutcomePredictorsIrritability DimensionHeadstrong DimensionCoefficient95% CIDifference Between Predictors (*p*)CBCL Subscalesβ95% CI*p*β95% CI*p*WithdrawnBaseline**0.32(0.21 to 0.43).009**0.04(−0.07 to 0.16).438**−0.27(−0.48 to 0.07).009**14 mo**0.25(0.13 to 0.37).027**−0.00(−0.12 to 0.12).958**−0.25(−0.48 to 0.03).027**Somatic ComplaintsBaseline0.16(0.04 to 0.27).6780.11(−0.00 to 0.23).059−0.04(−0.26 to 0.17).67814 mo0.18(0.06 to 0.31).087−0.01(−0.14 to 0.11).807−0.20(−0.43 to 0.03).087Anxious/DepressedBaseline**0.49(0.38 to 0.59).000**0.01(−0.09 to 0.11).841**−0.48(−0.66** to **−0.28).000**14 mo**0.38(0.26 to 0.50).000**−0.05(−0.17 to 0.07).405**−0.43(−0.65** to **0.21).000**Social ProblemsBaseline0.17(0.06 to 0.28).652**0.22(0.11 to 0.33).000**0.05(−0.15 to 0.25).65214 mo0.12(−0.00 to 0.24).6040.06(−0.06 to 0.18).348−0.06(−0.29 to 0.17).604Thought ProblemsBaseline0.18(0.07 to 0.30).4840.11(−0.01 to 0.22).071−0.08(−0.29 to 0.14).48414 mo0.10(−0.02 to 0.22).7180.06(−0.06 to 0.18).335−0.04(−0.27 to 0.18).718Attention ProblemsBaseline0.19(0.07 to 0.30).603**0.13(0.02 to 0.24).024**−0.05(−0.26 to 0.15).60314 mo0.15(0.03 to 0.28).2020.01(−0.12 to 0.13).912−0.15(−0.38 to 0.08).202Delinquent BehaviorBaseline**0.10(0.00 to 0.20).0000.44(0.34 to 0.54).0000.34(0.16** to **0.53).000**14 mo0.10(−0.01 to 0.22).100**0.28(0.17 to 0.40).000**0.18(−0.03 to 0.39).100Aggressive BehaviorBaseline0.34(0.25 to 0.42).274**0.42(0.34 to 0.51).000**0.08(−0.07 to 0.24).27414 mo0.24(0.12 to 0.35).738**0.27(0.16 to 0.38).000**0.03(−0.17 to 0.24).738Sex ProblemsBaseline0.06(0.06 to 0.30).289**0.18(0.06 to 0.30).003**0.12(−0.10 to 0.33).28914 mo0.03(−0.09 to 0.15).6170.09(0.03 to 0.21).1390.06(−0.17 to 0.27).617Internalizing Scale[a](#dtbl1fna){ref-type="table-fn"}Baseline**0.43(0.32 to 0.54).000**0.06(−0.04 to 0.17).244**0.37(−0.56** to **−0.17).000**14 mo**0.35(0.23 to 0.47).001**−0.03(−0.15 to 0.08).575**−0.39(−0.61** to **−0.17).001**Externalizing Scale[a](#dtbl1fna){ref-type="table-fn"}Baseline0.29(0.21 to 0.38).026**0.47(0.38 to 0.55).0000.17(0.02** to **0.32).026**14 mo0.22(0.10 to 0.33).456**0.29(0.18 to 0.40).000**0.07(−0.13 to 0.28).456Total ScoreBaseline0.35(0.26 to 0.44).802**0.33(0.23 to 0.42).000**−0.02(−0.19 to 0.15).80214 mo0.28(0.16 to 0.39).199**0.14(0.02 to 0.25).020**−0.14(−0.35 to 0.07).199[^1][^2]Table S2Parent-Reported Attention-Deficit/Hyperactivity Disorder (ADHD) Response to Multimodal Treatments Including Baseline Irritability as a Factor (3-Way Interaction Model: Irritability×Time×Treatment Group)Outcome: Parent-Reported ADHDχ^2^CoefficientCI*p*Omnibus Tests Time**30.54------.000** Treatment Group0.43------.934 Irritability**11.53------.001** Time×Treatment Group**20.51------.015** Time×Irritability1.45------.695 Irritability×Treatment Group0.90------.825 Time×Irritability×Treatment Group4.27------.893Decomposing Time×Treatment Group Interaction CC vs. MedMgt**---−0.38(−0.67** to **−0.09).011** CC vs. Beh---0.01(−0.28 to 0.29).969 CC vs. Comb**---−0.41(−0.71** to **−0.12).006** MedMgt vs. Beh**---0.43(0.14** to **0.74).004** MedMgt vs. Comb---0.06(−0.25 to 0.37).702 Beh vs. Comb**---0.38(0.07** to **0.69).016**Decomposing Irritability×Time×Treatment Group Interaction CC vs. MedMgt**---**−0.00(−0.06 to 0.05).877 CC vs. Beh---−0.01(−0.07 to 0.05).784 CC vs. Comb**---**−0.02(−0.08 to 0.04).481 MedMgt vs. Beh**---**−0.00(−0.06 to 0.05).898 MedMgt vs. Comb---−0.02(−0.07 to 0.04).567 Beh vs. Comb**---**0.01(−0.05 to 0.07).663[^3]Table S3Teacher-Reported Attention-Deficit/Hyperactivity Disorder (ADHD) Response to Multimodal Treatments Including Baseline Irritability as a Factor (3-Way Interaction Model: Irritability×Time×Treatment Group)Outcome: Teacher-Reported ADHDχ^2^CoefficientCI*p*Omnibus Tests Time**39.91------.000** Treatment Group2.38------.497 Irritability1.12------.291 Time×Treatment Group15.84------.070 Time×Irritability2.11------.551 Irritability×Treatment Group1.19------.754 Time×Irritability×Treatment Group6.51------.688Decomposing Time×Treatment Group Interaction CC vs. MedMgt**---−0.55(−0.91** to **−0.18).003** CC vs. Beh---−0.24(−0.61 to 0.13).198 CC vs. Comb---−0.30(−0.68 to 0.07).111 MedMgt vs. Beh---0.30(−0.05 to 0.66).092 MedMgt vs. Comb---0.24(−0.12 to 0.60).185 Beh vs. Comb---0.06(−0.05 to 0.66).739Decomposing Irritability×Time×Treatment Group Interaction CC vs. MedMgt**---**0.02(−0.05 to 0.09).644 CC vs. Beh---0.02(−0.05 to 0.10).535 CC vs. Comb**---**−0.01(−0.09 to 0.06).742 MedMgt vs. Beh**---**−0.01(−0.07 to 0.08).853 MedMgt vs. Comb---−0.03(−0.10 to 0.04).424 Beh vs. Comb**---**0.04(−0.04 to 0.11).346[^4]Figure S1Path analyses of the relation between irritability and headstrong dimensions across time.

The authors would like to thank Pablo Vidal-Ribas, MSc, of King\'s College London for important insights during analysis of the data. Data used in the preparation of this article (MTA96, version 1) were obtained from the limited access datasets of the MTA, which was a National Institute of Mental Health (NIMH) cooperative agreement randomized clinical trial involving 6 clinical sites. Collaborators from NIMH: Peter S. Jensen, MD (currently at REACH Institute and Mayo Clinic), L. Eugene Arnold, MD, MEd (currently at Ohio State University), Joanne B. Severe, MS (Clinical Trials Operations and Biostatistics Unit, Division of Services and Intervention Research), Benedetto Vitiello, MD (Child and Adolescent Treatment and Preventive Interventions Research Branch), John Richters, PhD (currently at National Institute of Nursing Research), Donald Vereen, MD (currently at National Institute on Drug Abuse). Principal investigators and co-investigators from the 6 sites were: University of California, Berkeley/San Francisco: Stephen P. Hinshaw, PhD (Berkeley), Glen R. Elliott, PhD, MD (San Francisco); Duke University: C. Keith Conners, PhD, Karen C. Wells, PhD, John March, MD, MPH; University of California, Irvine/Los Angeles: James Swanson, PhD (Irvine), Dennis P. Cantwell, MD, (deceased, Los Angeles), Timothy Wigal, PhD (Irvine); Long Island Jewish Medical Center/Montreal Children\'s Hospital: Howard B. Abikoff, PhD (currently at New York University School of Medicine), Lily Hechtman, MD (McGill University); New York State Psychiatric Institute/Columbia University/Mount Sinai Medical Center: Laurence L. Greenhill, MD (Columbia), Jeffrey H. Newcorn, MD (Mount Sinai School of Medicine); University of Pittsburgh: William E. Pelham, PhD (currently at Florida International University), Betsy Hoza, PhD (currently at University of Vermont). Statistical and design consultant: Helena C. Kraemer, PhD (Stanford University). Collaborator from the Office of Special Education Programs/US Department of Education: Ellen Schiller, PhD.

Clinical guidance is available at the end of this article.

Supplemental material cited in this article is available online.

Dr. Fernández de la Cruz was fully supported and Dr. Simonoff was partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley National Health Service (NHS) Foundation Trust and the Institute of Psychiatry, King's College London. The Multimodal Treatment Study of Children With ADHD (MTA) has been supported by the following grant numbers: U01MH50440, U01MH50447, U01MH50453, U01MH50454, U01MH50461, U01MH50467, and the following contract numbers: N01MH12004, N01MH12007, N01MH12008, N01MH12009, N01MH12010, N01MH12011, N01MH12012; HHSN271200800003-C, HHSN271200800004-C, HHSN271200800005-C, HHSN271200800006-C, HHSN271200800007-C, HHSN271200800008-C, and HHSN271200800009-C. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the Department of Health, the MTA Study Investigators, the National Institutes of Health (NIH), the NHS, or the NIHR.

John Hodsoll, PhD, of King's College London served as the statistical expert for this research.

Disclosure: Dr. McGough has received grant or research support from NIH, NeuroSigma, Inc., Purdue Pharma L.P., and Shire Pharmaceuticals. He has served as a consultant to Akili Interactive Labs, Merck, Neurovance, and Sunovion. He has presented expert testimony for Shire. Dr. Arnold has received research funding from Curemark, Forest, Eli Lilly and Co., Neuropharm, Novartis, Noven, Shire, Young Living, NIH, and Autism Speaks, and has consulted with or been on advisory boards for Gowlings, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and Tris Pharma, and has received travel support from Noven. Dr. Stringaris has received grant or research support from the Wellcome Trust, the NIHR, and the Department of Health UK. He has received royalties from Cambridge University Press for his book *The Maudsley Reader in Phenomenological Psychiatry*. Drs. Fernández de la Cruz, Simonoff, and Halperin report no biomedical financial interests or potential conflicts of interest.

![Parent-reported irritability response to multimodal treatment in the 4 treatment groups. Note: Beh = Behavioral treatment; CC = Community Comparison; Comb = Combined treatment; MedMgt = Medication management.](gr1){#fig1}

![Changes in parent-reported attention-deficit/hyperactivity disorder (ADHD) scores in the 4 treatment groups in individuals with high (a) and low (b) irritability. Note: The categorical outcome was generated using a median split into high and low irritability and is used in this figure for purposes of illustration. However, a dimensional irritability variable is used in the statistical models presented in the text. Beh = behavioral treatment; CC = community comparison; Comb = combined treatment; MedMgt = Medication management.](gr2){#fig2}

###### 

Irritability Response to Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment in the 4 Treatment Groups

                          Irritability Scores (SNAP Parent Report)                                                    
  ----------------------- ------------------------------------------ ------ ------ ------ ------ ------ ------ ------ ------
  Community comparison    4.40                                       2.43   3.77   2.53   3.83   2.56   3.28   2.18   0.48
  Medication management   4.40                                       2.65   2.81   2.37   2.75   2.26   2.80   2.39   0.63
  Behavioral treatment    4.11                                       2.44   3.39   2.31   3.25   2.20   3.11   2.41   0.42
  Combined treatment      4.26                                       2.41   3.02   2.05   2.64   2.08   2.35   2.22   0.82

  Treatment Group Comparison                       Between-Group Effect Size (Baseline to 14-Month Assessment)
  ------------------------------------------------ -------------------------------------------------------------
  Medication management vs. Community comparison   0.20
  Behavioral treatment vs. Community comparison    −0.05
  Combined treatment vs. Community comparison      0.34
  Medication management vs. Behavioral treatment   .24
  Combined treatment vs. Medication management     .13
  Combined treatment vs. Behavioral treatment      0.38

Note: SNAP = Swanson, Nolan, and Pelham rating scale.

###### 

Irritability Response to Attention-Deficit/Hyperactivity Disorder Treatment

  Outcome: Parent-Reported Irritability          χ^2^        Coefficient   CI                             *P*
  ---------------------------------------------- ----------- ------------- ------------------------------ ----------
  Omnibus Tests                                                                                           
   Time                                          **44.52**   **---**       **---**                        **.000**
   Treatment Group                               1.38        ---           ---                            .711
   Time×Treatment Group                          **33.66**   **---**       **---**                        **.000**
  Decomposing Time×Treatment Group Interaction                                                            
   CC vs. MedMgt                                 ---         −0.42         (−0.92 to 0.07)                .095
   CC vs. Beh                                    ---         0.16          (−0.33 to 0.65)                .515
   CC vs. Comb                                   **---**     −**0.71**     **(**−**1.20** to −**0.22)**   **.004**
   MedMgt vs. Beh                                **---**     **0.58**      **(0.09** to **1.01)**         **.021**
   MedMgt vs. Comb                               ---         −0.29         (−0.78 to 0.20)                .249
   Beh vs. Comb                                  **---**     **0.87**      **(0.39** to **1.36)**         **.000**

Note: Significant results are shown in boldface. Beh = behavioral treatment; CC = community comparison; Comb = combined treatment; MedMgt = Medication management.

###### 

Attention-Deficit/Hyperactivity Disorder (ADHD) Response to Multimodal Treatments Including Baseline Irritability as a Factor

  Outcome: Parent-Reported ADHD                  χ^2^         Coefficient   CI                         *p*
  ---------------------------------------------- ------------ ------------- -------------------------- ----------
  Omnibus Tests                                                                                        
   Time                                          **57.90**    **---**       **---**                    **.000**
   Treatment Group                               0.19         ---           ---                        .979
   Irritability                                  **21.06**    **---**       **---**                    **.000**
   Time×Treatment Group                          **123.41**   **---**       **---**                    **.000**
   Time×Irritability                             7.50         ---           ---                        .058
   Irritability×Treatment Group                  0.16         ---           ---                        .984
  Decomposing Time×Treatment Group Interaction                                                         
   CC vs. MedMgt                                 **---**      **−0.40**     **(−0.54** to **−0.25)**   **.000**
   CC vs. Beh                                    ---          **−**0.03     (−0.17 to 0.11)            .681
   CC vs. Comb                                   **---**      **−0.50**     **(−0.65** to **−0.36)**   **.000**
   MedMgt vs. Beh                                **---**      **0.37**      **(0.22** to **0.51)**     **.000**
   MedMgt vs. Comb                               ---          **−**0.11     (−0.25 to 0.03)            .136
   Beh vs. Comb                                  **---**      **0.48**      **(0.33** to **0.62)**     **.000**

  Outcome: Teacher-Reported ADHD                 χ^2^        Coefficient   CI                         *p*
  ---------------------------------------------- ----------- ------------- -------------------------- ----------
  Omnibus Tests                                                                                       
   Time                                          **87.06**   **---**       **---**                    **.000**
   Treatment Group                               1.17        ---           ---                        .620
   Irritability                                  1.05        ---           ---                        .305
   Time×Treatment Group                          **70.13**   **---**       **---**                    **.000**
   Time×Irritability                             3.10        ---           ---                        .377
   Irritability×Treatment Group                  1.65        ---           ---                        .648
  Decomposing Time×Treatment Group Interaction                                                        
   CC vs. MedMgt                                 **---**     **−0.47**     **(−0.65** to **−0.29)**   **.000**
   CC vs. Beh                                    ---         −0.14         (−0.32 to 0.04)            .125
   CC vs. Comb                                   **---**     **−0.35**     **(−0.53** to **−0.18)**   **.000**
   MedMgt vs. Beh                                **---**     **0.33**      **(0.15** to **0.51)**     **.000**
   MedMgt vs. Comb                               ---         0.12          (−0.06 to 0.30)            .204
   Beh vs. Comb                                  **---**     **0.21**      **(0.03** to **0.39)**     **.022**

Note: Significant results are shown in boldface. Beh = behavioral treatment; CC = community comparison; Comb = combined treatment; MedMgt = Medication management.

[^1]: Note: Significant results are shown in boldface.

[^2]: The Internalizing Scale is composed of the subscales Withdrawn, Somatic Complaints, and Anxious/Depressed Behavior. The Externalizing Scale is composed of the Delinquent Behavior and Aggressive Behavior scales.

[^3]: Note: Significant results are shown in boldface. Beh = behavioral treatment; CC = community comparison; Comb = combined treatment; MedMgt = medication management.

[^4]: Note: Significant results are shown in boldface. Beh = behavioral treatment; CC = community comparison; Comb = combined treatment; MedMgt = medication management.
